Bush, Ashley I.

Redox‐Active Metals, Oxidative Stress, and Alzheimer's Disease Pathology

HUANG, X., MOIR, R. D., TANZI, R. E., BUSH, A. I., & ROGERS, J. T. (2004) · Annals of the New York Academy of Sciences

Alzheimer's disease research and treatmentsTrace Elements in Health

Cited by 425

Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients

Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., et al. (2008) · Neuropsychopharmacology

Schizophrenia research and treatmentAmino Acid Enzymes and Metabolism

Cited by 371

Mitochondrial Oxidative Stress Causes Hyperphosphorylation of Tau

Melov, S., Adlard, P. A., Morten, K., Johnson, F., Golden, T. R., Hinerfeld, D., Schilling, B., Mavros, C., Masters, C. L., Volitakis, I., et al. (2007) · PLoS ONE

Alzheimer's disease research and treatmentsMitochondrial Function and Pathology

Cited by 363

Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion

Tuo, Q.-Z., Liu, Y., Xiang, Z., Yan, H.-F., Zou, T., Shu, Y., Ding, X.-L., Zou, J.-J., Xu, S., Tang, F., et al. (2022) · Signal Transduction and Targeted Therapy

Ferroptosis and cancer prognosisNeuroprotection in Cerebral Ischemia

Cited by 330

Metals and Alzheimer's disease

Adlard, P. A., & Bush, A. I. (2006) · Journal of Alzheimer's Disease

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 324

Metal complexing agents as therapies for Alzheimer’s disease

Bush, A. I. (2002) · Neurobiology of Aging

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 310

Degradation of the Alzheimer Disease Amyloid β-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity

White, A. R., Du, T., Laughton, K. M., Volitakis, I., Sharples, R. A., Xilinas, M. E., Hoke, D. E., Holsinger, R. M. D., Evin, G., Cherny, R. A., et al. (2006) · Journal of Biological Chemistry

Alzheimer's disease research and treatmentsProtease and Inhibitor Mechanisms

Cited by 284

Risk prediction of late-onset Alzheimer’s disease implies an oligogenic architecture

Zhang, Q., Sidorenko, J., Couvy-Duchesne, B., Marioni, R. E., Wright, M. J., Goate, A. M., Marcora, E., Huang, K.-L., Porter, T., Laws, S. M., et al. (2020) · Nature Communications

Alzheimer's disease research and treatmentsGenetic Associations and Epidemiology

Cited by 272

The role of metallobiology and amyloid-β peptides in Alzheimer's disease

Roberts, B. R., Ryan, T. M., Bush, A. I., Masters, C. L., & Duce, J. A. (2012) · Journal of Neurochemistry

Alzheimer's disease research and treatmentsTrace Elements in Health

Cited by 266

Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease

Ayton, S., Lei, P., Duce, J. A., Wong, B. X. W., Sedjahtera, A., Adlard, P. A., Bush, A. I., & Finkelstein, D. I. (2013) · Annals of Neurology

Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

Cited by 264

Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing

Brown, B. M., Peiffer, J. J., Taddei, K., Lui, J. K., Laws, S. M., Gupta, V. B., Taddei, T., Ward, V. K., Rodrigues, M. A., Burnham, S., et al. (2013) · Molecular Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 235

Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier

Li, J., Zheng, M., Shimoni, O., Banks, W. A., Bush, A. I., Gamble, J. R., & Shi, B. (2021) · Advanced Science

Barrier Structure and Function StudiesDrug Transport and Resistance Mechanisms

Cited by 202

Glutathione: a novel treatment target in psychiatry

Berk, M., Ng, F., Dean, O., Dodd, S., & Bush, A. I. (2008) · Trends in Pharmacological Sciences

Sulfur Compounds in BiologyRedox biology and oxidative stress

Cited by 183

The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial

Berk, M., Dean, O., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B. S., Kohlmann, K., Jeavons, S., Hewitt, K., Allwang, C., et al. (2011) · Journal of Affective Disorders

Bipolar Disorder and TreatmentTreatment of Major Depression

Cited by 181

GSK‐3 in Neurodegenerative Diseases

Lei, P., Ayton, S., Bush, A. I., & Adlard, P. A. (2011) · International Journal of Alzheimer’s Disease

Alzheimer's disease research and treatmentsWnt/β-catenin signaling in development and cancer

Cited by 177

The Efficacy of Adjunctive N-Acetylcysteine in Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Trial

Berk, M., Dean, O. M., Cotton, S. M., Jeavons, S., Tanious, M., Kohlmann, K., Hewitt, K., Moss, K., Allwang, C., Schapkaitz, I., et al. (2014) · The Journal of Clinical Psychiatry

Treatment of Major DepressionTryptophan and brain disorders

Cited by 172

Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease

Fowler, C., Rainey-Smith, S. R., Bird, S., Bomke, J., Bourgeat, P., Brown, B. M., Burnham, S. C., Bush, A. I., Chadunow, C., Collins, S., et al. (2021) · Journal of Alzheimer's Disease Reports

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 164

Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer’s disease

Huynh, K., Lim, W. L. F., Giles, C., Jayawardana, K. S., Salim, A., Mellett, N. A., Smith, A. A. T., Olshansky, G., Drew, B. G., Chatterjee, P., et al. (2020) · Nature Communications

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 154

Plasma apolipoprotein E and Alzheimer disease risk: The AIBL study of aging

Gupta, V. B., Laws, S. M., Villemagne, V. L., Ames, D., Bush, A. I., Ellis, K. A., Lui, J. K., Masters, C., Rowe, C. C., Szoeke, C., et al. (2011) · Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 149

Motor and cognitive deficits in aged tau knockout mice in two background strains

Lei, P., Ayton, S., Moon, S., Zhang, Q., Volitakis, I., Finkelstein, D. I., & Bush, A. I. (2014) · Molecular Neurodegeneration

Alzheimer's disease research and treatmentsParkinson's Disease Mechanisms and Treatments

Cited by 145

Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis

Dedeoglu, A., Cormier, K., Payton, S., Tseitlin, K. A., Kremsky, J. N., Lai, L., Li, X., Moir, R. D., Tanzi, R. E., Bush, A. I., et al. (2004) · Experimental Gerontology

Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

Cited by 141

Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies

Martins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., et al. (2018) · Journal of Alzheimer’s Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 129

BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease

Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Pietrzak, R. H., Ellis, K. A., Harrington, K. D., Bourgeat, P., Salvado, O., Darby, D., et al. (2013) · Neurobiology of Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 124

Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer’s Disease: A Preliminary Study

Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Pietrzak, R. H., Ellis, K. A., Harrington, K., Bourgeat, P., Bush, A. I., Martins, R. N., et al. (2014) · PLoS ONE

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 110